CABA · Cabaletta Bio, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $37.35M | - | $39.82M | $37.64M | $29.02M | - | $26.29M | $23.43M | $21.95M | - |
| SG&A | $6.94M | - | $6.76M | $8.27M | $8.12M | - | $6.76M | $6.85M | $6.08M | - |
| Total Operating Expenses | $44.30M | - | $46.59M | $45.91M | $37.14M | - | $33.05M | $30.28M | $28.03M | - |
| D&A | $337.0K | - | - | - | $485.0K | - | - | - | $393.0K | - |
| Operating Income | ($44.30M) | - | ($46.59M) | ($45.91M) | ($37.14M) | - | ($33.05M) | ($30.28M) | ($28.03M) | - |
| Interest Expense | $636.0K | - | $0 | $571.0K | $0 | - | - | - | - | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $0 | - |
| Net Income | ($43.52M) | - | ($44.87M) | ($45.13M) | ($35.94M) | - | ($30.63M) | ($27.60M) | ($25.05M) | - |
| EPS - Basic | ($0.39) | - | ($0.44) | ($0.73) | ($0.71) | - | ($0.62) | ($0.56) | ($0.51) | - |
| EPS - Diluted | ($0.39) | - | ($0.44) | ($0.73) | ($0.71) | - | ($0.62) | ($0.56) | ($0.51) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $116.64M | $82.98M | $60.21M | $145.61M | $131.83M | $163.96M | $170.61M | $178.61M | $175.29M | $193.24M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $6.38M | $6.64M | $8.27M | $7.19M | $6.49M | $4.92M | $2.18M | $4.22M | $5.84M | $4.55M |
| Current Assets | $122.32M | $138.87M | $164.56M | $198.41M | $134.60M | $166.68M | $185.51M | $206.26M | $227.48M | $244.49M |
| Total Assets | $148.15M | $165.08M | $189.76M | $224.50M | $165.14M | $185.05M | $204.41M | $217.42M | $240.46M | $253.65M |
| Current Liabilities | $41.51M | $50.15M | $45.73M | $41.54M | $33.99M | $27.09M | $22.88M | $17.90M | $17.97M | $15.99M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $44.84M | $53.03M | $50.29M | $46.02M | $43.59M | $32.71M | $30.17M | $17.90M | $18.74M | $17.45M |
| Stockholders' Equity | $103.31M | $112.05M | $139.47M | $178.48M | $121.55M | $152.34M | $174.24M | $199.52M | $221.72M | $236.20M |
| Retained Earnings | ($560.47M) | ($516.96M) | ($475.04M) | ($430.17M) | ($385.04M) | ($349.10M) | ($316.51M) | ($285.89M) | ($258.28M) | ($233.24M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($42.56M) | - | - | - | ($30.80M) | - | - | - | ($23.99M) | - |
| Investing Cash Flow | $50.96M | - | - | - | ($785.0K) | - | - | - | ($812.0K) | - |
| Financing Cash Flow | $25.27M | - | - | - | ($552.0K) | - | - | - | $6.86M | - |
| CapEx | $0 | - | - | - | $785.0K | - | - | - | $812.0K | - |
| Free Cash Flow | ($42.56M) | - | - | - | ($31.59M) | - | - | - | ($24.80M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.98 | - | - | - | 0.88 | - | - | - | 0.99 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -29.4% | - | -23.6% | -20.1% | -21.8% | - | -15.0% | -12.7% | -10.4% | - |
| Return on equity | -42.1% | - | -32.2% | -25.3% | -29.6% | - | -17.6% | -13.8% | -11.3% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.95 | 2.77 | 3.60 | 4.78 | 3.96 | 6.15 | 8.11 | 11.52 | 12.66 | 15.29 |
| Quick ratio | 2.95 | 2.77 | 3.60 | 4.78 | 3.96 | 6.15 | 8.11 | 11.52 | 12.66 | 15.29 |
| Cash ratio | 2.81 | 1.65 | 1.32 | 3.51 | 3.88 | 6.05 | 7.46 | 9.98 | 9.75 | 12.08 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -69.6x | - | - | -80.4x | - | - | - | - | - | - |
| Equity multiplier | 1.43 | 1.47 | 1.36 | 1.26 | 1.36 | 1.21 | 1.17 | 1.09 | 1.08 | 1.07 |
| Liabilities / Assets | 0.30 | 0.32 | 0.27 | 0.20 | 0.26 | 0.18 | 0.15 | 0.08 | 0.08 | 0.07 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 1.3x | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -19.3% | - | -41.0% | -51.6% | -32.5% | - | -77.0% | -90.6% | -65.3% | - |
| Net income growth (YoY) | -21.1% | - | -46.5% | -63.5% | -43.5% | - | -86.2% | -90.5% | -58.0% | - |
| EPS growth (YoY) | 45.1% | - | 29.0% | -30.4% | -39.2% | - | -67.6% | -51.4% | -13.3% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -34.7% | - | - | - | -27.4% | - | - | - | -90.9% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -15.0% | -26.4% | -20.0% | -10.5% | -45.2% | -35.5% | 8.3% | 14.6% | 141.9% | 126.0% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Cabaletta Bio against the 5 most active filers in the same SIC group.